For future research, it will be instructive to perform integrated multidimensional analyses of Yu103 EBV and the host cells it resides in; probing the antigenicity and immunogenicity of Yu103 EBV-driven tumors, and appraising the implications for EBV-directed cancer immunotherapies (3, 14–16); and investigating whether Yu103 is capable of transforming gastric epithelium, since the LMP1 deletion variant which it harbors has been detected in ~80% of EBV-associated gastric cancer cases in Asia (56, 57). This evidence concerns the gene PDLIM7 and gastric cancer.